BARDA Industry Day
We partner with companies and teams offering solutions to a broad range of national health security threats.
BARDA is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcment (BAA-18-100-SOL-00003)
Advanced manufacturing technologies
Therapeutics for novel coronavirus
BARDA supports advanced research and development of medical countermeasures and is a component of the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE).
If you or your company are developing a medical countermeasure, platform technology, or other innovative product in our mission space, you can engage BARDA and other PHEMCE partner agencies to gain technical feedback on what is presented and strategic input as to its relevance for our mission at a CoronaWatch/TechWatch meeting. This TechWatch web portal is serving as the single point of entry for interested entities submitting market research and meeting requests for the U.S. government COVID-19 medical countermeasures task force. At this time, we are not seeking submissions from medical countermeasure developers that do not pertain to COVID-19.
CoronaWatch meetings will be held via interactive webinar only, and we will be able to interactively display slides and manuscripts received electronically. Though not required, meetings generally have two phases. The first is a presentation from the meeting requestor to government personnel, which is informal and highly interactive. The second phase is a discussion among the participants. Scientific subject matter experts from the PHEMCE partner agencies (including BARDA) and contracting officers will attend. Additional details will be provided at the time a meeting is scheduled.
If you are interested in partnering with the federal government on a COVID-19 medical countermeasure, submit your ideas to a platform that reaches a host of potential federal partners.
To spur innovation, BARDA has issued its business-friendly, streamlined Easy Broad Agency Announcement (EZ-BAA) to support a number of new medical countermeasures to fight the COVID-19 outbreak.